Transformation of greenhouse gas CO2 and renewable H2 into fuels and commodity chemicals is recognized as a promising route to store fluctuating renewable energy. Although several C1 chemicals, olefins, and gasoline have been successfully synthesized by CO2 hydrogenation, selective conversion of CO2 and H2 into aromatics is still challenging due to the high unsaturation degree and complex structures of aromatics. Here we report a composite catalyst of ZnAlOx and H-ZSM-5 which yields high aromatics selectivity (73.9%) with extremely low CH4 selectivity (0.4%) among the carbon products without CO. Methanol and dimethyl ether, which are synthesized by hydrogenation of formate species formed on ZnAlOx surface, are transmitted to H-ZSM-5 and subsequently converted into olefins and finally aromatics. Furthermore, 58.1% p-xylene in xylenes is achieved over the composite catalyst containing Si-H-ZSM-5. ZnAlOx&H-ZSM-5 suggests a promising application in manufacturing aromatics from CO2 and H2.

[reaction: see text] The 2,2,2-trichloroethyl (TCE) group was utilized as the first protecting group for aryl sulfates. Aryl sulfates, protected with the TCE group, were prepared in high yield by reacting phenols with chlorosulfuric acid TCE ester. Deprotection was accomplished using Pd/C-ammonium formate or with Zn-ammonium formate to give aryl sulfate monoesters in high yield. This approach to aryl sulfate synthesis was successfully applied to the construction of estrone sulfate derivatives, which could not be prepared by previous methodologies.

Ganoderma lucidum is an edible medicinal mushroom known as “Lingzhi” in China and “Reishi or Manetake” in Japan. It is a highly prized vitality‐enhancing herb for more than 2000 years. G. lucidum polysaccharide (GLPS) has been identified as one of the major bioactive components and developed into a drug named “Ji 731 Injection” in China since 1973. The large‐scale production of the drug began in 1985 and approved by the Chinese FDA as “Polysaccharidum of G. lucidum Karst Injection” (Ling Bao Duo Tang Zhu She Ye) in 2000, which is applied intramuscularly. After more than forty years of clinical use, its efficacy, safety and long‐term tolerability have been recognized by neurologists. It is one of a few non‐hormonal drugs used for treating refractory myopathy. It is also used for combination therapy, which reduces the amount of glucocorticoid required for myopathy patient who is in remission. In addition, it reduces adverse reactions and improves the quality of life for cancer patients during chemotherapy. We found 81 qualified chemical, biochemical, preclinical and clinical studies of GLPS both in English and in Chinese spanning from 1973 to 2017 by searching CNKI (China National Knowledge Infrastructure), Wanfang database and PubMed. The molecular mechanisms underlying GLPS's antioxidant, anti‐tumour, immune‐modulatory, hypoglycaemic, hypolipidaemic and other activities are discussed. Both preclinical and clinical studies are either deliberated or indexed in the current article. We aimed at providing a molecular picture as well as a clinical basis to comprehend GLPS as one of few polysaccharide‐based modern medicines with complicated chemical and pharmacological properties that prevent it from entering the world's market.